{"nctId":"NCT01930188","briefTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2013-12-02","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":1231,"armGroups":[{"label":"Semaglutide 0.5 mg + sitagliptin placebo","type":"EXPERIMENTAL","interventionNames":["Drug: semaglutide","Drug: placebo"]},{"label":"Semaglutide 1.0 mg + sitagliptin placebo","type":"EXPERIMENTAL","interventionNames":["Drug: semaglutide","Drug: placebo"]},{"label":"Sitagliptin 100 mg + semaglutide placebo 1.0 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: sitagliptin","Drug: placebo"]},{"label":"Sitagliptin 100 mg + semaglutide placebo 0.5 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: sitagliptin","Drug: placebo"]}],"interventions":[{"name":"semaglutide","otherNames":[]},{"name":"sitagliptin","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: - Japan: Age minimum 20 years - Subjects diagnosed with type 2 diabetes and on stable treatment in a period of 90 days prior to screening with either metformin above or equal to 1500 mg (or maximum tolerated dose), pioglitazone above or equal to 30 mg (or maximum tolerated dose), rosiglitazone above or equal to 4 mg (or maximum tolerated dose) or a combination of either metformin/pioglitazone or metformin/rosiglitazone (doses as for individual therapies). Stable is defined as unchanged medication and unchanged dose - HbA1c 7.0 - 10.5 % (53 - 91 mmol/mol) (both inclusive) Exclusion Criteria: - Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using an adequate contraceptive method throughout the trial including the 5 weeks follow-up period (adequate contraceptive measures as required by local law or practice) - Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol - Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 90 days before screening. An exception is short-term treatment (below or equal to 7 days in total) with insulin in connection with inter-current illness - History of chronic or idiopathic acute pancreatitis - Screening calcitonin value above or equal to 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) - Impaired renal function defined as estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m2 per modification of diet in renal disease (MDRD) formula (4 variable version) - Acute coronary or cerebrovascular event within 90 days before randomisation - Heart failure, New York Heart Association (NYHA) class IV","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c (Glycosylated Haemoglobin) From Baseline","description":"Change in HbA1c from baseline until week 56.Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of randomised semaglutide or sitagliptin.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.32","spread":"0.05"},{"groupId":"OG001","value":"-1.61","spread":"0.05"},{"groupId":"OG002","value":"-0.55","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline","description":"Change in body weight from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.28","spread":"0.25"},{"groupId":"OG001","value":"-6.13","spread":"0.25"},{"groupId":"OG002","value":"-1.93","spread":"0.26"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline","description":"Change in fasting plasma glucose from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.38","spread":"1.79"},{"groupId":"OG001","value":"-46.72","spread":"1.78"},{"groupId":"OG002","value":"-19.85","spread":"1.88"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic and Diastolic Blood Pressure From Baseline","description":"Change in systolic and diastolic blood pressure from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.07","spread":"0.64"},{"groupId":"OG001","value":"-5.61","spread":"0.63"},{"groupId":"OG002","value":"-2.29","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.01","spread":"0.42"},{"groupId":"OG001","value":"-1.91","spread":"0.42"},{"groupId":"OG002","value":"-1.11","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Change in Patient Reported Outcome (PRO) Questionnaire Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) From Baseline","description":"Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin. The DTSQs questionnaire was used to assess subjects' treatment satisfaction. This questionnaire contained 8 components and evaluates the diabetes treatment (including insulin, tablets and/or diet) in terms of convenience, flexibility and general feelings towards the treatment. The result presented is the 'Treatment Satisfaction' summary score, which is the sum of 6 of the 8 items of the DTSQs questionnaire. Response options range from 6 (best case) to 0 (worst case). Total scores for treatment satisfaction range from 0-36. Higher scores indicate higher satisfaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.28","spread":"0.23"},{"groupId":"OG001","value":"5.91","spread":"0.23"},{"groupId":"OG002","value":"4.45","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieved HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target (Yes/no)","description":"Subjects who achieved HbA1c â‰¤6.5% (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) target (yes/no) after week 56 weeks of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"270","spread":null},{"groupId":"OG002","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"194","spread":null},{"groupId":"OG001","value":"139","spread":null},{"groupId":"OG002","value":"324","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":30,"n":409},"commonTop":["Nausea","Diarrhoea","Nasopharyngitis","Lipase increased","Vomiting"]}}}